ClinicalTrials.gg
RecruitingNCT06742710LITOPUpdated May 29, 2025

Liraglutide Treatment in Obese Infertile PCOS Women

A Phase 4 interventional study of Liraglutide and metformin and Metformin in PCOS, Obesity and Infertility, sponsored by Peking University Third Hospital. Recruiting at 3 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Peking University Third Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
890
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Planned enrollment
2nd of 79
890 · median 70
Started
2025
with 1 other
Phase 4
37 of 79
4 open now
Registered
76th of 79
by date

Among the 79 studies testing liraglutide in Obesity, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 37 in phase 4, and was the 76th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.

Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.

03

Conditions studied

  • PCOS
  • Obesity
  • Infertility

Keywords

  • polycystic ovary syndrome
  • liraglutide
  • infertile
  • obesity
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with polycystic ovary syndrome (PCOS) who meet the Rotterdam diagnostic criteria.
  • Aged 20-40 years;
  • 25 kg/m2 ≤ ≤ 35 kg/m2;
  • Have not used any anti-diabetes or weight-loss medications (metformin excluded) within the past 3 months;
  • Have at least 1 transplantable frozen embryo available at the research center;
  • Able to follow the study's requirements.

Exclusion criteria

Exclusion Criteria:

  • Diabetic ketoacidosis or other acute complications of diabetes;
  • ≥ 9.0% before enrollment;
  • Using drugs that affect appetite or nutrient absorption within the past 2 months (metformin excluded);
  • Uncontrolled hyperthyroidism or hypothyroidism, hypertension, systemic diseases, etc. that may affect pregnancy and fetal development;
  • 17 hydroxyprogesterone in follicualr phase > 2.0 ng/ml;
  • Serious cardiovascular, digestive, liver, or kidney diseases, -positive chronic hepatitis B, active pulmonary tuberculosis, or AIDS, etc. that are infectious or hereditary diseases;
  • Any psychiatric or psychological disorders requiring drug treatment;
  • Poor pregnancy and delivery history: recurrent failed implantations ≥3 times, spontaneous abortions ≥2 times; history of stillbirth, dystocia, or birth defects; previous pregnancies with preeclampsia, eclampsia, or HELLP syndrome;
  • Uncontrolled metabolic, autoimmune, or hereditary disease in the husband;
  • A or relative contraindication to using GLP-1 receptor agonists (history of medullary thyroid carcinoma or family history of medullary thyroid carcinoma, acute cholecystitis or pancreatitis in the acute phase or history of previous attacks, GLP-1 receptor agonist allergy, etc.);
  • Failure to comply with the requirements of the study design;
  • Failure to take medication regularly and follow up;
  • Current smokers, drug addicts, alcoholics, or individuals with substance abuse;
  • Participants who have participated in any clinical trial within the past 3 months prior to screening;
  • Individuals with other conditions deemed unsuitable for participation in this clinical trial by the investigator;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
890 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Liraglutide 3.0 mg or maximum tolerable dose/day and metformin 1500 mg/day

    Drug: Liraglutide and metformin

  • Active comparator
    Control Group

    Metformin 1500 mg/day

    Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Live birth rate associated with single cycle frozen embryo transfer

    The rate of live birth of intervention and control groups

    Time frame: At delivery

Secondary outcomes

  1. Clinical pregnancy rate of single cycle frozen embryo transfer

    Viable intrauterine pregnancy confirmed by ultrasound

    Time frame: Thirty days after the embryo transplantation

  2. Incidence of newly diagnosed diabetes or gestational diabetes during pregnancy

    Newly diagnosed diabetes or gestational diabetes at 28 weeks of pregnancy confirmed by 75 g oral glucose tolerance test。

    Time frame: At 28 weeks of pregnancy

  3. Pregnancy outcome and complications

    Rate of miscarriage, multiple pregnancies, pregnancy induced hypertension, preeclampsia, HELLP syndrome, prematurity (\< 37 weeks), macrosomia (birth weight \> 4 kg), induction of labour, prolonged duration of labour, caesarean section, assisted delivery, peripartum increased blood loss (≥ 800 ml).

    Time frame: From baseline to delivery

  4. Birth weight for gestational age

    Birth weight percentile for gestational age for neonatal sex

    Time frame: At delivery

  5. Apgar scores

    Apgar scores (0\~10) of the newborns at delivery

    Time frame: At delivery

  6. Other perinatal outcomes

    Rate of major birth defects, stillbirth, neonatal complications, and neonatal admission to a neonatal intensive care unit.

    Time frame: At delivery

  7. Accumulated live birth rate

    Accumulated liver birth rate associated with the pregnancy achieved during the first 6 months of the study

    Time frame: At delivery

  8. Accumulated clinical pregnancy rate

    Accumulated clinical pregnancy rate achieved during the first 6 months of the study

    Time frame: At month 6

Other outcomes

  1. Weight

    Measured by the same weight scale

    Time frame: At baseline, and week 12

  2. Oral glucose tolerance test

    oral glucose tolerance test was conducted to test glucose metabolism

    Time frame: At baseline, week 12, 28 weeks of pregnant, six weeks after delivery

  3. HbA1c

    Glycosylated hemoglobin

    Time frame: At baseline and week12

  4. Rate of insulin usage during pregancy

    Time frame: Throughout pregnancy

  5. Number of menstrual cycles

    Time frame: From to 12 weeks

  6. Free testosterone index

    Free testosterone index

    Time frame: At baseline, week 12

  7. Drug-related adverse reactions

    Drug-related adverse reactions, including but not limited to, nausea, diarrhea, vomiting, decreased appetite, dyspepsia, constipation, drug allergy, hypoglycemia, acute pancreatitis, acute gallbladder disease.

    Time frame: During the treatment with liraglutide or metformin

  8. Anxiety

    Measured by Generalized Anxiety Disorder-7 scores, from 0 (no anxiety) to 21 (severe anxiety)

    Time frame: Baseline and week 12

  9. Depression

    Measured by Patient Health Questionnaire-9 score from 0 (no depression) to 27 (severe depression)

    Time frame: Baseline and week 12

  10. Quality of life specifically for PCOS individuals

    Measured by Modified Polycystic ovary syndrome Quality of life, with each item scores from 1 (maximum impairment) to 7 (no impairment)

    Time frame: Baseline and week 12

  11. Major congenital malformations

    Identified in the Birth Defects Prevention and Control Plan (2023-2027) issued by the National Health Commission of the People's Republic of China

    Time frame: Six weeks after live birth

  12. Costs

    The cost per live birth for the different intervention groups, considering both direct medical and non-medical costs, as well as indirect costs.

    Time frame: At delivery

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual participant data will be available if researchers provide a methodologically sound proposal and contact to the principal investigator. Data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 48 months is above that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2024
First posted
Dec 19, 2024
StartActual
May 22, 2025
Primary completionEst.
May 30, 2029
CompletionEst.
Dec 31, 2029
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742710
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
May 22, 2025
Primary completion
May 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 29, 2025

Study contacts

Haining Wang, Professor
Contact
hainingmail@bjmu.edu.cn
8601082265025
Ye Liu, Associate Professor
Contact
yeliumed@bjmu.edu.cn
8601082265025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liraglutide · Metformin

Start the discussion